Mankind Pharma Limited · NSE: MANKIND · BSE: 543904

Mankind Pharma

Quarterly results as filed with BSE. Latest: Q1 FY27 (Apr–Jun 2026), filed 30 Jul 2026.

Q1 FY27 · Consolidated

Revenue
4,030.59₹ Cr
+12.9% vs year ago
Net profit
574.09₹ Cr
+29.1% vs year ago
EPS, basic
13.76₹
+29.6% vs year ago
Net margin
14.2%
+1.8 pts vs year ago
Revenue₹ crore · consolidated · last 12 quarters
Q2 FY24: ₹2,708.10 CrQ3 FY24: ₹2,606.96 CrQ4 FY24: ₹2,441.10 CrQ1 FY25: ₹2,893.42 CrQ2 FY25: ₹3,076.51 CrQ3 FY25: ₹3,230.00 CrQ4 FY25: ₹3,079.37 CrQ1 FY26: ₹3,570.35 CrQ2 FY26: ₹3,697.16 CrQ3 FY26: ₹3,567.20 CrQ4 FY26: ₹3,442.93 CrQ1 FY27: ₹4,030.59 CrQ3 ’24Q1 ’25Q3 ’25Q1 ’26Q3 ’26Q1 ’27
Net profit₹ crore · consolidated · last 12 quarters
Q2 FY24: ₹511.18 CrQ3 FY24: ₹459.81 CrQ4 FY24: ₹476.59 CrQ1 FY25: ₹543.07 CrQ2 FY25: ₹658.88 CrQ3 FY25: ₹384.52 CrQ4 FY25: ₹424.65 CrQ1 FY26: ₹444.62 CrQ2 FY26: ₹520.18 CrQ3 FY26: ₹413.88 CrQ4 FY26: ₹559.42 CrQ1 FY27: ₹574.09 CrQ3 ’24Q1 ’25Q3 ’25Q1 ’26Q3 ’26Q1 ’27

Quarter by quarter

Consolidated · ₹ crore
QuarterRevenueYoYNet profitYoYEPS (₹)Filed
Q1 FY27Apr–Jun 20264,030.59+12.9%574.09+29.1%13.7630 Jul 2026
Q4 FY26Jan–Mar 20263,442.93+11.8%559.42+31.7%13.4419 May 2026
Q3 FY26Oct–Dec 20253,567.20+10.4%413.88+7.6%9.9003 Feb 2026
Q2 FY26Jul–Sep 20253,697.16+20.2%520.18−21.1%12.3906 Nov 2025
Q1 FY26Apr–Jun 20253,570.35+23.4%444.62−18.1%10.6231 Jul 2025
Q4 FY25Jan–Mar 20253,079.37+26.1%424.65−10.9%10.1925 Jun 2025
Q3 FY25Oct–Dec 20243,230.00+23.9%384.52−16.4%9.4524 Jan 2025
Q2 FY25Jul–Sep 20243,076.51+13.6%658.88+28.9%16.3105 Nov 2024
Q1 FY25Apr–Jun 20242,893.42+12.2%543.07+9.9%13.3922 Aug 2024
Q4 FY24Jan–Mar 20242,441.10+18.9%476.59+62.3%11.7617 May 2024
Q3 FY24Oct–Dec 20232,606.96—459.81—11.3312 Feb 2024
Q2 FY24Jul–Sep 20232,708.10—511.18—12.5101 Nov 2023
Q1 FY24Apr–Jun 20232,578.62—494.19—12.1502 Aug 2023
Q4 FY23Jan–Mar 20232,052.67—293.70—7.1330 May 2023
Standalone results
Standalone · ₹ crore
QuarterRevenueYoYNet profitYoYEPS (₹)Filed
Q1 FY27Apr–Jun 20262,964.05+16.6%558.49+35.3%13.5330 Jul 2026
Q4 FY26Jan–Mar 20262,581.82+21.4%713.61+86.6%17.2919 May 2026
Q3 FY26Oct–Dec 20252,632.68+9.9%449.47+7.9%10.8903 Feb 2026
Q2 FY26Jul–Sep 20252,608.78+3.1%458.90−27.7%11.1206 Nov 2025
Q1 FY26Apr–Jun 20252,541.36+5.7%412.76−19.6%10.0031 Jul 2025
Q4 FY25Jan–Mar 20252,126.59−1.2%382.46−15.8%18.5425 Jun 2025
Q3 FY25Oct–Dec 20242,396.57+1.6%416.38−14.5%10.3524 Jan 2025
Q2 FY25Jul–Sep 20242,529.74+3.1%634.43+34.2%15.8405 Nov 2024
Q1 FY25Apr–Jun 20242,403.26+4.5%513.49+25.5%12.8222 Aug 2024
Q4 FY24Jan–Mar 20242,152.69+15.0%454.17+61.6%11.3417 May 2024
Q3 FY24Oct–Dec 20232,358.57—487.07—12.1612 Feb 2024
Q2 FY24Jul–Sep 20232,453.35—472.88—11.8001 Nov 2023
Q1 FY24Apr–Jun 20232,300.21—409.28—10.2202 Aug 2023
Q4 FY23Jan–Mar 20231,872.12—280.99—7.0130 May 2023

28 filings on record for this company.